Analyst Price Target is €130.25
▼ -34.00% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for MERCK Kommanditgesellschaft auf Aktien in the last 3 months. The average price target is €130.25, with a high forecast of €144.00 and a low forecast of €102.00. The average price target represents a -34.00% upside from the last price of €197.35.
Current Consensus is
The current consensus among 9 polled investment analysts is to hold stock in MERCK Kommanditgesellschaft auf Aktien. This Hold consensus rating has held steady for over two years.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.